Innate Pharma S.A. IPHYF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 5.78% | -2.22% | -23.02% | -19.80% | 9.12% |
| Total Depreciation and Amortization | -11.44% | -3.92% | -13.23% | -15.50% | -34.72% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -122.87% | -124.81% | 62.60% | 58.34% | 6,211.28% |
| Change in Net Operating Assets | 91.19% | 90.45% | -69.21% | -70.01% | -156.20% |
| Cash from Operations | 30.80% | 24.92% | -137.40% | -131.18% | -1,182.35% |
| Capital Expenditure | -58.97% | -72.79% | 17.19% | 19.36% | 78.40% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -69.10% | -66.48% | -94.82% | -94.96% | 510.25% |
| Cash from Investing | -70.17% | -67.64% | -95.84% | -95.95% | 688.98% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 46.95% | 46.95% | 1.35% | 1.35% | -0.81% |
| Issuance of Common Stock | -- | -- | -98.27% | -98.27% | 15,955.91% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -123.13% | -125.09% | -186.25% | -178.74% | 355.28% |
| Foreign Exchange rate Adjustments | -125.37% | -127.52% | 130.79% | 130.01% | 519.31% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -74.66% | -89.49% | -678.45% | -658.06% | -2,072.64% |